Am I right in thinking that the FDA will not require CXS to retest again? Will CXS present the FDA with the updated data (released last December with bigger sample size) showing a much better cytogenetic response in chronic phase patients with the mutation? Or will the FDA still vote on the original data submitted? ie. will an entirely new NDA be required?
t315i mutation testing , page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)